Haematology News and Research RSS Feed - Haematology News and Research

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
Study: Brain tumors hijack the brain's existing blood supply during progression

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time. [More]
5-LO enzyme plays important role in the survival of leukaemic AML stem cells

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse. [More]
Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. [More]

Beckman Coulter Life Sciences launches Aquios CL Clinical Flow Cytometer* for laboratory use

Beckman Coulter Life Sciences is set to transform the use of flow cytometry in the routine clinical laboratory with its latest offering, the Aquios CL Clinical Flow Cytometer*. Fully automated, with a small footprint, the instrument is the first authentic ‘LOAD & GO’ cytometry system. [More]
EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency). [More]
Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology. [More]
Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences. [More]
Genetic evidence confirms role of group of virus-fighting genes in cancer development

Genetic evidence confirms role of group of virus-fighting genes in cancer development

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. [More]
New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life. [More]
CLL patients more prone to infections due to reduced number of antibodies

CLL patients more prone to infections due to reduced number of antibodies

People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes. [More]
Researchers identify two novel genes associated with development of rare, aggressive blood cancer

Researchers identify two novel genes associated with development of rare, aggressive blood cancer

R​esearchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly targeted therapies that are directed at just one target fail. [More]
Researchers investigate stickiness of leukaemia cells and its link to drug resistance

Researchers investigate stickiness of leukaemia cells and its link to drug resistance

Researchers in Manchester have investigated the stickiness of leukaemia cells, and whether this is linked to drug resistance. [More]
Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology, a provider of innovative genetics research solutions, today announced the acquisition of Cambridge-based Cytocell Limited, a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer. [More]
Report calls for better palliative and EOL care for patients that relapse following transplant

Report calls for better palliative and EOL care for patients that relapse following transplant

Haematological disorders of the blood and bone marrow, such as leukaemia, are commonly treated with a bone marrow transplant. However relapse is common and often leads to treatment failure and death. [More]
CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis. [More]
Elsevier launches open access journal, Pathogenesis

Elsevier launches open access journal, Pathogenesis

Elsevier, world-leading provider of scientific, technical and medical information products and services, announces the launch of open access journal, Pathogenesis. [More]
Scientists develop novel treatment for Hairy Cell Leukaemia using drug administered to combat skin cancer

Scientists develop novel treatment for Hairy Cell Leukaemia using drug administered to combat skin cancer

A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. [More]
NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI® (pixantrone). [More]
Market research report on injectable generic and biosimilar drugs

Market research report on injectable generic and biosimilar drugs

Reportlinker.com announces that a new market research report is available in its catalogue: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 [More]